Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells

International Journal of Oncology

Volumn 39, Issue 3, 2011, Pages 561-568

  Kamigaki, Michihiro ^a   Sasaki, Tamito ^a   Serikawa, Masahiro ^a   Inoue, Motoki ^a   Kobayashi, Kenso ^a   Itsuki, Hiroshi ^a   Minami, Tomoyuki ^a   Yukutake, Masanobu ^a   Okazaki, Akihito ^a   Ishigaki, Takashi ^a   Ishii, Yasutaka ^a   Kosaka, Keiichi ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Caspase 3; Cholangiocarcinoma; ERK; Statins

Indexed keywords

ATORVASTATIN; CASPASE 3; CISPLATIN; FLUOROURACIL; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; PITAVASTATIN; STATIN;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INCUBATION TIME; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; WESTERN BLOTTING;

APOPTOSIS; CASPASE 3; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASTIC STEM CELLS; PYRROLES; QUINOLINES;

EID: 79960020540     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1087     Document Type: Article

References (40)

1. Rial NS, Henderson JT, Bhattacharyya AK, et al: Use of endoscopic ultrasound for diagnosis of cholangiocarcinoma in auto-immune hepatitis. World J Gastrointestinal Endosc 2: 404-407, 2010.
2. Morise Z, Sugioka A, Tokoro T, et al: Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol 2: 58-64, 2010.
3. Valle J Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281, 2010.
4. Watanabe Y, Ito T, Shiomi M, et al: Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim Biophys Acta 960: 294-302, 1988.
5. Hoeg JM and Brewer HB Jr: 3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors in the treatment of hypercho lesterolemia. JAMA 258: 3532-3536, 1987. (Pubitemid 18007514)
6. Khush KK and Waters DD: Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J Card Fail 12: 664-674, 2006. (Pubitemid 44512141)
7. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622, 1998. (Pubitemid 28248586)
8. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335: 1001-1009, 1996. (Pubitemid 26338729)
9. Mason RP, Walter MF and Jacob RF: Effects of HMG-CoA reductase inhibitors on endothelial function: role of micro-domains and oxidative stress. Circulation 109: II34-II41, 2004.
10. Hindler K, Cleeland CS, Rivera E and Collard CD: The role of statins in cancer therapy. Oncologist 11: 306-315, 2006.
11. Mo H and Elson CE: Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med 229: 567-585, 2004. (Pubitemid 38878903)
12. Demierre MF, Higgins PD, Gruber SB, Hawk E and Lippman SM: Statins and cancer prevention. Nat Rev Cancer 5: 930-942, 2005. (Pubitemid 41766782)
13. Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, Koronkiewicz M, Jakobisiak J and Golab J: Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 24: 1149-1157, 2004.
14. Sivaprasad U, Abbas T and Dutta A: Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 5: 2310-2316, 2006. (Pubitemid 44530468)
15. Keyomarsi K, Sandoval L, Band V and Pardee AB: Synchronization of tumour and normal cells from Gl to multiple cell cycles by lovastatin. Cancer Res 51: 3602-3609, 1991.
16. Muck AO, Seeger H and Wallwiener D: Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 42: 695-700, 2004. (Pubitemid 39625129)
17. Koyuturk M, Ersoz M and Altiok N: Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci Lett 370: 212-217, 2004. (Pubitemid 39370881)
18. Campbell MJ, Esserman LJ, Zhou Y, et al: Breast cancer growth prevention by statins. Cancer Res 66: 8707-8714, 2006. (Pubitemid 44449187)
19. Werner M, Sacher J and Hohenegger M: Mutual amplification of apoptosis by statin induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharm 143: 715-724, 2004. (Pubitemid 39611607)
20. Kusama T, Mukai M, Iwasaki T, etal: 3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122: 308-317, 2002. (Pubitemid 34116983)
21. Paragh G, Kertai P, Kovacs P, Paragh G Jr, Fulop P and Foris G: HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats. Anticancer Res 23: 3949-3954, 2003. (Pubitemid 37474348)
22. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD and Rennert HS: Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-2192, 2005. (Pubitemid 40727085)
23. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC and Giovannucci E Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98: 1819-1825, 2006.
24. Khurana V, Sheth A, Caldito G and Barkin JS: Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 34: 260-265, 2007. (Pubitemid 46294804)
25. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K and Yamazaki M: Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1045: 115-120, 1990. (Pubitemid 20218819)
26. Wise C, Pilanthananond M, Perry BF, et al: Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol 14 2986-2989, 2008.
27. Duan SG, Long Cheng, et al: The role of MAPK-ERK pathway in 67-kDa laminin receptor-induced FasL expression in human cholangiocarcinoma cells. Dig Dis Sci 55: 2844-2852, 2010.
28. Murakami M, Sasaki T, Yamasaki S, et al: Induction of apoptosis by ionizing radiation and CI-1033 in HuCCT-1 cells. Biochem Biophys Res Comm 319: 114-119, 2004 (Pubitemid 38670167)
29. Miyata H, Sasaki T, Kuwahara K, et al: The effect of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines. Int J Oncol 28: 915-921, 2006.
30. Minichsdorfer C and Hohenegger M: Autocrine amplification loop in statin-induced apoptosis of human melanoma cells. Br J Pharmacol 157: 1278-1290, 2009.
31. Schachter M: Chemical pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19: 17-125, 2005.
32. Koyuturk M, Ersoz M and Altiok N: Simvastatin induces apoptosis in human breast cancer cells: P53 and estrogen receptor independent pathway requiring signaling through JNK. Cancer Lett 250: 220-228, 2006.
33. Duncan RE, El-Sohemy A and Archer MC: Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem 279: 33079-33084, 2004. (Pubitemid 39062951)
34. Duncan RE, El-Sohemy A and Archer MC: Statins and cancer development. Cancer Epidemiol. Biomarkers Prev 14 1897-1898, 2005.
35. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyorala K and Wedel H: Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86: 257-262, 2000. (Pubitemid 30462217)
36. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, et al: Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7: 158-167, 2001. (Pubitemid 32110219)
37. Wong WW, Clendening JW, Martirosyan A, Boutros PC, Bros C, Khosravi F, et al: Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther 6: 1886-1897, 2007.
38. Chan KK, Oza AM and Siu LL: The statins as anticancer agents, Clin Cancer Res 9: 10-19, 2003. (Pubitemid 36109711)
39. Issat T, Nowis D, Legat M, et al: Potentiated antitumor effects of the combination treatment with statins and Pamidronate in vitro and in vivo. Int J Oncol 30: 1413-1425, 2007.
40. Mistefa O and Stenius U: Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem Pharmacol 78: 1115-1126, 2009.